# Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children

> **NCT03476135** · PHASE3 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 91 (actual)

## Conditions studied

- Meningococcal Infections

## Interventions

- **BIOLOGICAL:** MenACYW conjugate vaccine

## Key facts

- **NCT ID:** NCT03476135
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-27
- **Primary completion:** 2018-09-10
- **Final completion:** 2018-09-10
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2022-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03476135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03476135, "Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03476135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*